Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether à-go-go-1 potassium channels.

Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether à-go-go-1 potassium channels. Cell Mol Biol (Noisy-le-grand). 2017 Dec 17;63(12):11-13 Authors: Bernal-Ramos G, Hernández-Gallegos E, Vera E, Chávez-López MG, Zúñiga-García V, Sánchez-Pérez Y, Garrido E, Camacho J Abstract Prostate cancer (PC) is the main cause of cancer mortality in men worldwide. Therefore, novel treatments for PC are needed. Ether à-go-go-1 (Eag1) potassium channels display oncogenic properties, and have been suggested as early tumor markers and therapeutic targets for different cancers. These channels are overexpressed in many human tumors including PC. Astemizole targets several molecules involved in cancer including Eag1 channels, histamine receptors and ABC transporters. Here we studied Eag1 mRNA expression and protein levels in the non-tumorigenic and non-invasive human prostate RWPE-1 cell line, and in the tumorigenic and highly invasive human prostate WPE1-NB26 cell lines. The effect of astemizole on cell proliferation and apoptosis was also studied. The human prostate cell lines RWPE-1 and WPE1-NB26 were cultured following the provider´s instructions. Eag1 mRNA expression and protein levels were studied by real time RT-PCR and immunocytochemistry, respectively. Cell proliferation and apoptosis were studied by a fluorescence AlamarBlue®  assay and flow cy...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Related Links:

Reuters Health Information
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistributi...
Source: Clinics - Category: General Medicine Source Type: research
Publication date: Available online 21 September 2018Source: The Lancet HIVAuthor(s): Nancy A Hessol, Hannah Whittemore, Eric Vittinghoff, Ling C Hsu, Danning Ma, Susan Scheer, Sandra K SchwarczSummaryBackgroundCancer survivors are at increased risk for subsequent primary cancers. People living with HIV are at increased risk for AIDS-defining and non-AIDS-defining cancers, but little is known about their risk of first versus second primary cancers. We identified first and second primary cancers that occurred in above population expected numbers among people diagnosed with HIV in San Francisco, and compared first and second ...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research
Publication date: Available online 19 September 2018Source: Molecular and Cellular EndocrinologyAuthor(s): Trevor M. PenningAbstractAldo-Keto-Reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase (HSD)/prostaglandin (PG) F2α synthase) is the only 17β-HSD that is not a short-chain dehydrogenase/reductase. By acting as a 17-ketosteroid reductase, AKR1C3 produces potent androgens in peripheral tissues which activate the androgen receptor (AR) or act as substrates for aromatase. AKR1C3 is implicated in the production of androgens in castration-resistant prostate cancer (CRPC) and polycystic ovarian syndrome; a...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
shi Kobayashi Second-generation androgen receptor axis-targeted (ARAT) agents, namely abiraterone and enzalutamide, enable stronger blockade of the androgen receptor (AR) axis and longer survival of men with castration-resistant prostate cancer (CRPC). However, the extent of the improved survival remains insufficient and the majority of patients eventually develop resistance to these novel agents. Some patients develop resistance against ARAT treatment through mechanisms termed “complete AR independence” or “AR indifference”, and no longer require activation of the AR axis. Howev...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
A systematic review and meta-analysis was performed to determine the relationship between testosterone therapy and risk of recurrence in testosterone-deficient survivors of curatively treated high-risk prostate cancer. Primary outcome was the risk of biochemical recurrence (BCR) in 109 high-risk patients in 13 included studies (1997-2017). Biochemical and symptomatic effects of therapy were also reviewed. The BCR rate was 0.00 (0.00-0.05), lower than the expected rate for high-risk prostate cancer survivors, suggesting that testosterone therapy may not increase their BCR risk.
Source: Urology - Category: Urology & Nephrology Authors: Tags: Review Source Type: research
Radical prostatectomy (RP) and radiotherapy (RT) represent the main treatment modalities for localized prostate cancer (CaP) [1]. RT is also used in the adjuvant setting for patients with pT3 CaP or positive surgical margins, and as salvage treatment for biochemical failure after RP. As treatments become more effective, the increase in survivorship has led to the observation of second primary malignancies (SPMs) in cancer survivors. Radiation is believed to contribute to development of SPMs, and studies have shown relationships between radiation, urothelial dysplasia, and DNA damage [2,3].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Source Type: research
The objectives are to assess the feasibility of radical prostatectomy (RP) after VTP and describe functional and oncological outcomes.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
Initiation of expression of fibroblast growth factor receptor 1 (FGFR1) concurrent with loss of FGFR2 expression is a well-documented event in the progression of prostate cancer (PCa). Although it is known that some FGFR isoforms confer advantages in cell proliferation and survival, the mechanism by which the subversion of different FGFR isoforms contributes to PCa progression is incompletely understood. Here, we report that fibroblast growth factor (FGF) promotes NF-κB signaling in PCa cells and that this increase is associated with FGFR1 expression. Disruption of FGFR1 kinase activity abrogated both FGF activity an...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Cell Biology Source Type: research
Enzalutamide treatment for the whole spectrum of CRPC, Published online: 21 September 2018; doi:10.1038/s41585-018-0090-1The FDA recently expanded the indication for enzalutamide for the treatment of all men with metastatic and nonmetastatic castration-resistant prostate cancer on the basis of the PROSPER trial. Now that both disease states can have the same treatment, the need to thoroughly identify metastatic lesions is questioned.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Molecular Biology | Nanotechnology | Potassium | Prostate Cancer